ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MNKD vs SNDX // FORWARD P/E MULTIPLE

MannKind Corporation (NASDAQ) VS. Syndax Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: MNKD 6 — SNDX 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MNKD VS. SNDX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MNKD SNDX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 92.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 54.50% -35.00% +89.50 MNKD /roic <GO>
EV/EBITDA & P/E Valuation 24.6x — — TIE /valuation <GO>
Free Cash Flow Yield 1.22% — — TIE /fcf-yield <GO>
Operating Margin 11.10% -60.00% +71.10 MNKD /operating-margins <GO>
Net Profit Margin 1.70% -60.00% +61.70 MNKD /net-margins <GO>
Revenue Growth (YoY) 22.20% 180.00% -157.80 SNDX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 3/9 +4.00 MNKD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 61.7 34.3 +27.40 MNKD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.17B $1.17B $3.8M MNKD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MNKD REV SNDX REV MNKD GROSS % SNDX GROSS % MNKD FCF SNDX FCF
FY 2025 $349.0M $172.4M 92.3% — $13.7M -$323.2M
FY 2024 $285.5M $23.7M 93.9% — $32.8M -$274.9M
FY 2023 $199.0M $643.9M — — $34.1M -$160.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MNKD // BETA —
SNDX // BETA —